Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy

Table 3 Comparison of liver histology at baseline and after long-term treatment in both entecavir and lamivudine arms n (%)

	ETV (n = 19)	LAM ± ADV (n = 23)
Change in necroinflammation
Median grade (range)	11 (0-16)1 to 0 (0-4)1	9 (3-12)2 to 3 (0-12)2
Improved	18 (94.74)	19 (82.61)
No change	1 (5.26)	4 (17.39)
Worsened	0 (0)	0 (0)
Change in fibrosis
Median stage (range)	4 (2-6)3 to 3 (0-5)3	5 (2-6) 4 to 3 (0-6)4
Improved	13 (68.42)	11 (47.83)
No change	5 (26.32)	9 (39.13)
Worsened	1 (5.26)	3 (13.04)

¹Comparison of change in necroinflammation at baseline and after long-term treatment in ETV arm, P = 0.0002;

²Comparison of change in necroinflammation at baseline and after long-term treatment in LAM arm, P < 0.0001;

³Comparison of change in fibrosis at baseline and after long-term treatment in ETV arm, P = 0.0019;

⁴Comparison of change in fibrosis at baseline and after long-term treatment in LAM arm, P = 0.0205. ETV: Entecavir; LAM: Lamivudine; ADV: Adefovir.